Therapeutic microencapsulation of embedding parathyroid live cells with theracyte and a manufacturing method thereof

• US 20070207126A1
• Filed: 03/02/2006
• Published: 09/06/2007
• Est. Priority Date: 03/02/2006
• Status: Abandoned Application

• Current Assignee: Non-Profit Organization Chang Gung Memorial Hospital
• Original Assignee: Non-Profit Organization Chang Gung Memorial Hospital
• Inventors: Chou, Fong-Fu
• Application Number:
  US11/366,231
• Publication Number:
  US 20070207126A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/55 Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L

Abstract

A therapeutic microencapsulation for embedding parathyroid live cells with TheraCyte® and a manufacturing method are disclosed, where in the agent is made by embedding at least 4×10⁵ parathyroid live cells with TheraCyte®. The achieved agent can be planted into mammal objects for treating osteoporosis in long-term. The manufacturing method is characterized by immerging the parathyroid live gland in composition of Roswell Park Memorial Institute solution (85%), dimethyl sulfoxide (10%) and fetal calf serum 5% and depositing in −179° C. liquid nitrogen. The frozen parathyroid gland is sliced to pieces to isolate the live cells after unfreezing and then the parathyroid live cells are embedded with TheraCyte® to achieve the therapeutic microencapsulation.

Claims

1. A therapeutic microencapsulation is made by embedding at least 4×

10⁵ parathyroid live cells in TheraCyte®

, wherein the parathyroid live cells are contained in −

179°

C. liquid nitrogen and then unfrozen for preparing the therapeutic microencapsulation.

2. The therapeutic microencapsulation as claimed in claim 1, wherein the therapeutic microencapsulation contains 4×

10⁶ parathyroid live cells.

3. The therapeutic microencapsulation as claimed in claim 1, wherein the therapeutic microencapsulation contains at least 200×

4×

10⁵ parathyroid live cells for treating humans.

4. The therapeutic microencapsulation as claimed in claim 1, wherein the therapeutic microencapsulation contains 200×

4×

10⁶ parathyroid live cells for treating humans.

5. A manufacturing method for therapeutic microencapsulation comprising steps of:

obtaining a parathyroid gland, wherein the parathyroid gland is obtained by separating a heaviest parathyroid gland in surgery from a mammal having repeating hyperparathyroidism;

refrigerating the parathyroid gland, wherein the parathyroid gland is immerged by a composition composed of Roswell Park Memorial Institute solution (85%), dimethyl sulfoxide (10%) and fetal calf serum (5%) and contained in −

179°

C. liquid nitrogen;

isolating the parathyroid cells, wherein the refrigerated parathyroid gland is refrozen and sliced into piece to isolate the parathyroid cells, microspheres are suspended in a full-growth solution and then a trypsin/EDTA 0.05 solution is used to separate individualize parathyroid live cells; and

embedding to achieve the therapeutic microencapsulation, wherein 4×

10⁵ parathyroid live cells are embedded in Theracyte®

to achieve the therapeutic microencapsulation.

6. The manufacturing method as claimed in claim 5, wherein the sliced parathyroid gland after unfreezing is treated with collagenase II to isolate parathyroid cells.

7. The manufacturing method as claimed in claim 5, wherein an amount of the parathyroid live cells is calculated by an excluding method of trypan blue after separating the parathyroid cells with a trypsin/EDTA 0.05% solution.